CAK adds an activating phosphate to the complex, while Wee adds an inhibitory phosphate; the presence of both activating and inhibitory phosphates renders the complex inactive. Cdc25 is a phosphatase that removes the inhibitor phosphate added by Wee, rendering the complex active.
Cdk feeds back on Wee and Cdc25 to inhibit and enhance their respective activities.
|G1||D, E||CDK4, CDK2, CDK6|
Although it was originally developed as a potential anti-cancer drug, in recent laboratory tests Seliciclib has also proven to induce apoptosis in neutrophil granulocytes which mediate inflammation. This means that novel drugs for treatment of chronic inflammation diseases such as arthritis or cystic fibrosis could be developed. More research is required, however, because disruption of the CDK-mediated pathway has potentially serious consequences; while CDK inhibitors seem promising, it has to be determined how side effects can be limited so that only target cells are affected. As such diseases are currently treated with glucocorticoids, which have often serious side effects, even a minor success would mean an improvement.
US Patent Issued to Pirimal Life Sciences on Feb. 8 for "Inhibitors of Cyclin Dependent Kinases and Their Use" (Indian Inventors)
Feb 14, 2011; ALEXANDRIA, Va., Feb. 14 -- United States Patent no. 7,884,127, issued on Feb. 8, was assigned to Pirimal Life Sciences Ltd....
US Patent Issued to Piramal Life Science on March 29 for "Inhibitors of Cyclin Dependent Kinases and Their Use" (Indian Inventors)
Apr 04, 2011; ALEXANDRIA, Va., April 4 -- United States Patent no. 7,915,301, issued on March 29, was assigned to Piramal Life Science Ltd....